Add to ORKGrt-PA within 6 hours of acute ischemic stroke did not improve clinical outcomes at 6 months IST-3 collaborative group; Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
BACKGROUND: Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for us...
Rationale Intravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes i...
intravenous tissue-type plasminogen activator (tPA) window from 3 to 4.5 hours for patients with acu...
Background Intravenous recombinant tissue plasminogen activator (rt-PA) is approved ...
Abstract Background Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use...
BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger ...
Background Thrombolysis is of net benefi t in patients with acute ischaemic stroke, who are younger ...
ABSTRACT: BACKGROUND: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for u...
SummaryBackgroundThrombolysis is of net benefit in patients with acute ischaemic stroke, who are you...
BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger ...
BACKGROUND:Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger t...
Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use in patient...
Randomized, controlled trials and subsequent observational studies in routine clinical practice have...
Abstract Background Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europ...
Background: Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for us...
BACKGROUND: Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for us...
Rationale Intravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes i...
intravenous tissue-type plasminogen activator (tPA) window from 3 to 4.5 hours for patients with acu...
Background Intravenous recombinant tissue plasminogen activator (rt-PA) is approved ...
Abstract Background Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use...
BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger ...
Background Thrombolysis is of net benefi t in patients with acute ischaemic stroke, who are younger ...
ABSTRACT: BACKGROUND: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for u...
SummaryBackgroundThrombolysis is of net benefit in patients with acute ischaemic stroke, who are you...
BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger ...
BACKGROUND:Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger t...
Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use in patient...
Randomized, controlled trials and subsequent observational studies in routine clinical practice have...
Abstract Background Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europ...
Background: Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for us...
BACKGROUND: Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for us...
Rationale Intravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes i...
intravenous tissue-type plasminogen activator (tPA) window from 3 to 4.5 hours for patients with acu...